Tag: Athira Pharma
Alzheimer’s disease clinical trials, Part 1 with Dr. Cherian Verghese
Suzanne Newman joins Dr. Cherian Verghese to talk about a special program for those who are in the beginning or medium stages of Alzheimer's disease. Dr. Verghese is Principal Researcher at Keystone Clinical Studies LLC in the Philadelphia area. His mother died from Alzheimer's disease five years ago, and it transformed his efforts as a physician-investigator. Keystone is almost entirely focused on Alzheimer's. This segment concerns the differences between dementia and Alzheimer's, and how the disease progresses. The prevalence of Alzheimer's dementia is 5% in people 65 years old. By the age of 80, it's 40% or more.
Clinical trials for Alzheimer’s disease, Part 2 with Dr. Danielle Goldfarb
In this segment, Alzheimer's disease and dementia expert Dr. Danielle Goldfarb talks about clinical trials. Dr. Goldfarb is a neurologist and psychiatrist, as well as a physician researcher at Banner Sun Health Research Center in Sun Sun City, Arizona. Clinical trials are the cutting edge of new treatments and breakthroughs. In this segment Dr. Goldfarb talks about some of the promising latest news in clinical trials.
Clinical trials for Alzheimer’s disease, Part 1 with Dr. Danielle Goldfarb
In this segment, Alzheimer's disease and dementia expert Dr. Danielle Goldfarb talks about clinical trials. Dr. Goldfarb is a neurologist and psychiatrist, as well as a physician researcher at Banner Sun Health Research Center in Sun Sun City, Arizona. Clinical trials in an option for some patients, and it’s beneficial to participate. Dr. Goldfarb talks about what happens when you're considering taking part to help determine whether a newly-developed drug is safe, well-tolerated and effective.
New Athira Pharma Drug Trial for Parkinson’s, with Dr. Arif Khan
Dr. Arif Khan at the Northwest Clinical Research Center talks about Parkinson’s disease and an exciting clinical study by Athira Pharma for the treatment of Parkinson's Disease Dementia (PDD) and Dementia with Lewy Bodies. The medicine is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function. It's a new approach, potentially targeting the root cause of memory decline by repairing brain cells and rebuilding brain networks.
Alzheimer’s Disease, with Dr. Arif Kahn
Suzanne speaks with Dr. Arif Kahn, Adjunct Professor of Clinical Medicine at the Pacific Northwest University of Health Sciences. Dr. Khan has been conducting clinical trials in the greater Seattle area since 1984 and founded the NorthWest Clinical Research Center in 1995. He has been the Principal Investigator in over 600 clinical trials and has published more than 175 scientific papers in leading medical journals. He is also a Board Certified Psychiatrist and an Adjunct Professor of Psychiatry at Duke University School of Medicine.
Clinical Trials, with Dr. David Greeley
In this segment, Dr. David Greeley, MD, FAAN, founder of Northwest Neurological, focuses on the details of clinical trials and what they mean for you and your family. Northwest Neurological in Spokane, Washington provides medical services to patients with neurological concerns — especially movement disorders (Parkinson's disease, tremor, etc.) and dementia (such as Alzheimer's disease and Dementia with Lewy Bodies).
Alzheimer’s Disease, with Dr. Charles Bernick
Suzanne speaks with Dr. Charles Bernick, MD, MPH, a clinical professor at the University of Washington Department of Neurology who has researched Alzheimer's Disease and treatments for 25 years. He is Director of Clinical Trials for the Memory & Brain Wellness Clinic and a co-investigator at the Alzheimer’s Disease Research Center.
Wanted: Mild to Moderate Alzheimer’s Patients for Clinical Trials!
If you have a loved one or friend who has Alzheimer’s disease you may be interested in a brand-new cutting edge clinical study being conducted by Athira Pharma. Athira is a biopharmaceutical company focused on developing therapies to restore neuronal health and stop neurodegeneration. The company’s goal is to alter the course of neurological diseases and dementias, such as Alzheimer’s, so that patients can regain their memories, lives and family relationships.